aibio
Debt Financing ·
Co-Diagnostics issues senior secured convertible note to J.J. Astor
The note has an original principal amount of $2,835,000, repaid in weekly installments of $94,500. The final maturity date is May 7, 2027.
CODX Co-Diagnostics, Inc.
Co-Diagnostics (CODX) news CODX convertible notes news
Latest Co-Diagnostics news
- Debt Financing
Co-Diagnostics takes up to $3.1 million in secured convertible loans
J.J. Astor & Co. is the lender. The initial note carries a $2.835 million principal amount, and the company says the proceeds will fund working capital.
- Company Updates
Co-Diagnostics and ReadyGo to evaluate blood testing for Ebola
The companies will test whether ReadyGo's sample-preparation technology can work with the Co-Dx PCR platform on blood samples. Compatibility has not yet been established.
- Company Updates
Co-Diagnostics reports second quarter 2026 results and flu and RSV test submission
The net loss was $6.3 million, or $1.46 per share, and cash and cash equivalents were $3.6 million at June 30, 2026. The company said it submitted a 510(k) for its flu A/B and RSV test.
- Financings
Co-Diagnostics warrant inducement expected to raise about $2.67 million
Holders of existing warrants agreed to exercise at $1.571 per share in exchange for new warrants at $1.56. Maxim Group LLC is the exclusive placement agent.
- Company Updates
Co-Diagnostics reports first quarter 2026 results and $8.2 million in cash
The net loss was $9.1 million, or $4.06 per share, and cash and cash equivalents were $8.2 million at March 31, 2026. The company said enrollment in its upper respiratory test studies is complete.
Co-Diagnostics annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $622,489 | $3.9 million |
| Research and development | $19.1 million | $21.0 million |
| Net income (loss) | -$46.9 million | -$37.6 million |
| Cash from operations | -$29.1 million | -$29.2 million |
| Cash and equivalents | $11.9 million | $2.9 million |
| Short-term investments | $26.8 million |
Questions about Co-Diagnostics
Has Co-Diagnostics sold convertible notes?
Our latest story on this, dated Oct 9, 2026: "Co-Diagnostics issues senior secured convertible note to J.J. Astor". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Co-Diagnostics?
Co-Diagnostics, Inc. trades under the ticker CODX on NASDAQ.
Where is Co-Diagnostics listed?
Co-Diagnostics, Inc. is listed on NASDAQ.
Which country or territory is Co-Diagnostics listed under?
Our directory records Co-Diagnostics, Inc. under United States.
Does aibio.space cover Co-Diagnostics?
aibio.space lists Co-Diagnostics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
What was Co-Diagnostics's revenue last year?
$622,489 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Co-Diagnostics profitable?
Co-Diagnostics, Inc. reported a net loss of $46.9 million for the fiscal year ended Dec 31, 2025, and used $29.1 million of cash in operations, per its annual report to the SEC.
How much does Co-Diagnostics spend on research and development?
$19.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Co-Diagnostics have?
$3.6 million in cash at Jun 30, 2026, per its 10-Q.
What is the latest Co-Diagnostics (CODX) stock news?
Our latest story on Co-Diagnostics, dated Oct 9, 2026: "Co-Diagnostics issues senior secured convertible note to J.J. Astor". The note has an original principal amount of $2,835,000, repaid in weekly installments of $94,500. The final maturity date is May 7, 2027. Source.
What is Co-Diagnostics's latest stock offering or financing news?
Our latest financing story, dated Jul 31, 2026: "Co-Diagnostics warrant inducement expected to raise about $2.67 million". Holders of existing warrants agreed to exercise at $1.571 per share in exchange for new warrants at $1.56. Maxim Group LLC is the exclusive placement agent. Source.
Who were the underwriters or placement agents on Co-Diagnostics's offering?
From our story: Co-Diagnostics, Inc., a Utah corporation, issued a senior secured convertible note to J.J. Astor & Co., the lender, with an original issue date of October 9, 2026. Source.
How can I follow Co-Diagnostics (CODX) news?
Press Follow on this page to add Co-Diagnostics to your Following list, or subscribe to the aibio.space newsletter. We have published 6 stories naming Co-Diagnostics so far, in Company Updates, Debt Financing, Financings.
Investor discussion: Co-Diagnostics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
- Financings
Reported a financing. SEC Form 424B5. Source
Stock chart
Listing details
- Company
- Co-Diagnostics, Inc.
- Ticker
- CODX
- Listing
- NASDAQ
- Country or territory
- United States
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction